Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease

Antoniu, Sabina A; Râjnoveanu, Ruxandra; Ulmeanu, Ruxandra; Mihălţan, Florin; Grigore, Mihaela

doi:10.1080/14656566.2020.1745185

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the cognitive safety of this drug has been reported in numerous studies [55][56][57][58] , but no study met our inclusion criteria for this systematic review. Also, to the best of our knowledge, the cognitive safety of revefenacin, a long-acting muscarinic antagonist for the treatment of COPD, is not yet assessed in clinical trials 59 .…”

Section: Discussionmentioning

confidence: 99%

Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis

Naseri

Sadigh-Eteghad

Seyedi‐Sahebari

et al. 2023

Dement. neuropsychol.

View full text Add to dashboard Cite

ABSTRACT. Anticholinergics (ACs) are among the most prescribed drugs. Investigating the impaired cognitive domains due to individual ACs usage is associated with controversial findings. Objective: The objective of this study was to investigate the effects of individual ACs on different aspects of cognitive function based on clinical trial studies. Methods: This systematic review was conducted following the PRISMA statement. A systematic search was performed in Embase, PubMed, Cochrane Library, Scopus, and Web of Science databases. Risk of bias (RoB) was assessed by the Joanna Briggs Institute checklists and the meta-analysis was performed using the CMA software. Results: Out of 3,026 results of searching, 138 studies were included. A total of 38 studies that assess the cognitive impacts of scopolamine were included in the meta-analysis. Included studies reported cognitive effects of scopolamine, mecamylamine, atropine, biperiden, oxybutynin, trihexyphenidyl, benzhexol, and dicyclomine; however, glycopyrrolate, trospium, tolterodine, darifenacin, fesoterodine, tiotropium, and ipratropium were not associated with cognitive decline. Based on the meta-analyses, scopolamine was associated with reduced recognition (SDM -1.84; 95%CI -2.48 to -1.21; p<0.01), immediate recall (SDM -1.82; 95%CI -2.35 to -1.30; p<0.01), matching to sample (SDM -1.76; 95%CI -2.57 to -0.96; p<0.01), delayed recall (SDM -1.54; 95%CI -1.97 to -1.10; p<0.01), complex memory tasks (SDM -1.31; 95%CI -1.78 to -0.84; p<0.01), free recall (SDM -1.18; 95%CI -1.63 to -0.73; p<0.01), cognitive function (SDM -0.95; 95%CI -1.46 to -0.44; p<0.01), attention (SDM -0.85; 95%CI -1.38 to -0.33; p<0.01), and digit span (SDM -0.65; 95%CI -1.21 to -0.10; p=0.02). There was a high RoB in our included study, especially in terms of dealing with possible cofounders. Conclusion: The limitations of this study suggest a need for more well-designed studies with a longer duration of follow-up on this topic to reach more reliable evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis

Naseri

Sadigh-Eteghad

Seyedi‐Sahebari

et al. 2023

Dement. neuropsychol.

View full text Add to dashboard Cite

show abstract

“…The revefenacin database includes one 52week phase III comparison with tiotropium DPI in typical patients with moderate to very severe COPD, showing a numerically smaller lung-function improvement (trough FEV1) at the end of the treatment period and no difference in other outcomes. However, in a 28day phase IIIb, which recruited patients with COPD and suboptimal peak inspiratory flow rate (<60 l/min), nebulized revefenacin was superior to tiotropium DPI in improving trough FEV1 (significant in the subgroup with very low peak inspiratory flow rate (33-45 l/min) independent of COPD severity (Antoniu et al, 2020). To be noted, no similar comparisons were made with LAMAs in other devices (e.g., MDIs or SMIs) that also do not require the patient's breathing effort to disperse the particles into fine aerosols.…”

Section: Therapeutic Use Of Inhaled Muscarinic Acetylcholine Receptor Antagonists (Table 6)mentioning

confidence: 94%

“…Revefenacin, which is provided as solution in a unit dose vial (UDV) for once-daily inhalation by nebulizer in COPD, is the only nonquaternary LAMA. Although based on a smaller database, it is similarly profiled for efficacy, in other words, improvement in lung-function and HRQoL, reduction in breathlessness and dyspnea, and safety (based on a review by Antoniu et al, 2020). The compound offers a fast onset of action discussed as an advantage in symptomatic patients.…”

Section: Therapeutic Use Of Inhaled Muscarinic Acetylcholine Receptor Antagonists (Table 6)mentioning

confidence: 99%

Inhaled Medicines: Past, Present, and Future

Anderson

Atkins

Bäckman

et al. 2022

Pharmacological Reviews

View full text Add to dashboard Cite

Anderson previously received 13.2% share of the royalties received by the Sydney Local Health District (the owner of the intellectual property) for the use of mannitol to promote mucociliary clearance, and she is the inventor on the patent. She also owns shares of Pharmaxis Ltd worth less than US $5,000 that she purchased herself. Cipolla is a paid employee of Insmed Inc. Two of Insmed's products were discussed in these sections, including amikacin liposome inhalation suspension (ALIS, ARIKAYCE) and inhaled treprostinil palmitil. Daviskas received 16% share of the royalties received by the Sydney Local Health District (about US $10,000 per annum). She also owns shares of Pharmaxis worth less than US $3,000 that she purchased herself. Disse received compensation for consultant services from Boehringer Ingelheim, Actelion and Sanofi-Aventis in recent years. Olsson is owner of Mimetikos AB mentioned in the text.dx.

show abstract

Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease

Cited by 2 publications

References 18 publications

Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis

Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis

Inhaled Medicines: Past, Present, and Future

Contact Info

Product

Resources

About